secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001326110-26-000014
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio amends $505M convertible note to allow partial conversion at any time
--------------------------------------------------------------------------------

- Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.
- Previously, partial conversion was not permitted under the December 2024 note; no other terms changed.
- Holder Nant Capital is an affiliate of Executive Chairman Dr. Patrick Soon-Shiong, making this a related-party transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/ibrx-20260123.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer